438 related articles for article (PubMed ID: 25115145)
21. Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face.
Jim On SC; Hashim PW; Nia JK; Lebwohl MG
J Drugs Dermatol; 2017 May; 16(5):432-436. PubMed ID: 28628678
[TBL] [Abstract][Full Text] [Related]
22. Ingenol mebutate: from common weed to cancer cure.
Zarchi K; Jemec GB
Curr Probl Dermatol; 2015; 46():136-42. PubMed ID: 25561218
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Histologic Evaluation of Ingenol Mebutate 0.015% Gel for the Cosmetic Improvement of Photoaged Skin.
Handler MZ; Bloom BS; Goldberg DJ
Dermatol Surg; 2018 Jan; 44(1):61-67. PubMed ID: 28858927
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body.
Pellacani G; Peris K; Guillen C; Clonier F; Larsson T; Venkata R; Puig S
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2192-8. PubMed ID: 26300464
[TBL] [Abstract][Full Text] [Related]
25. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
[TBL] [Abstract][Full Text] [Related]
26. [Rapidly growing squamous cell carcinoma after ingenol mebutate treatment].
Ehret M; Velter C; Tebacher M; Bruant-Rodier C; Cribier B
Ann Dermatol Venereol; 2018 Oct; 145(10):607-612. PubMed ID: 29779859
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.
Bucko AD; Jarratt M; Stough DB; Kyhl L; Villumsen J; Hall A
J Dermatolog Treat; 2018 Feb; 29(1):74-79. PubMed ID: 28524709
[TBL] [Abstract][Full Text] [Related]
28. Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives.
Gameiro L; Tovo LFR; Sanches Júnior JA; Aprahamian I
An Bras Dermatol; 2019 Jul; 94(3):313-319. PubMed ID: 31365660
[TBL] [Abstract][Full Text] [Related]
29. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
[TBL] [Abstract][Full Text] [Related]
30. Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response.
Pampena R; Benati E; Borsari S; Bombonato C; Lombardi M; Raucci M; Mirra M; Lallas A; Apalla Z; Papadimitriou I; Moscarella E; Kyrgidis A; Argenziano G; Pellacani G; Longo C
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1461-1468. PubMed ID: 29356164
[TBL] [Abstract][Full Text] [Related]
31. Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques.
Ruini C; Hartmann D; Bastian M; Ruzicka T; French LE; Berking C; von Braunmühl T
J Biophotonics; 2019 Jul; 12(7):e201800391. PubMed ID: 30653833
[TBL] [Abstract][Full Text] [Related]
32. Ingenol Mebutate 500 µg on the Cheekbones with Concomitant Conjunctivitis.
Gaide O; Cattin V
Dermatology; 2016; 232 Suppl 1():4-6. PubMed ID: 27513756
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
34. Clinical Response to Ingenol Mebutate in Patients With Actinic Keratoses.
Batalla A; Flórez Á; Feal C; Peón G; Abalde MT; Salgado-Boquete L; de la Torre C
Actas Dermosifiliogr; 2015 Dec; 106(10):e55-61. PubMed ID: 26055975
[TBL] [Abstract][Full Text] [Related]
35. Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate.
Woo YR; Lim JH; Jeong SW; Cho DH; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1012-1017. PubMed ID: 28370377
[TBL] [Abstract][Full Text] [Related]
36. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.
Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M
J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403
[TBL] [Abstract][Full Text] [Related]
37. A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis.
Sinnya S; Tan JM; Prow TW; Primiero C; McEniery E; Selmer J; Østerdal ML; Soyer HP
Br J Dermatol; 2016 Feb; 174(2):305-11. PubMed ID: 26499175
[TBL] [Abstract][Full Text] [Related]
38. Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel.
Segura S; Gadea A; Nonell L; Andrades E; Sánchez S; Pujol R; Hernández-Muñoz I; Toll A
PLoS One; 2020; 15(5):e0232146. PubMed ID: 32413042
[TBL] [Abstract][Full Text] [Related]
39. Ingenol Mebutate: Expanded Utility.
Khalfe Y; Rosen T
J Drugs Dermatol; 2020 Feb 1 j; 19(2):156-161. PubMed ID: 32129959
[TBL] [Abstract][Full Text] [Related]
40. Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects.
Saraiva MIR; Portocarrero LKL; Vieira MAHB; Swiczar BCC; Westin AT
An Bras Dermatol; 2018; 93(4):529-534. PubMed ID: 30066759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
